NCT01558947.

Trial name or title	Peri‐operative chemotherapy with ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the treatment of advanced gastric cancer: a randomized, multicentre, parallel vontrol
Methods	Allocation: Randomised Intervention Model: Parallel assignment Masking: Single‐blind (participant) Primary Purpose: Treatment
Participants	Gastric cancer participants, ≥ T2 or N +; or staging II, IIIA, IIIB.
Interventions	Experimental: chemotherapy with ECX Preoperative chemotherapy of ECX for 3 cycles (Epirubicin 50 mg/m² on day 1; capecitabine 1000 mg/m², 2 times /day, 1 to 14 days; cisplatin 60 mg/m² on day 1, need hydration, 21 day/cycle), operation after 2˜4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4˜6 weeks after surgery. Experimental: chemotherapy with XP Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000 mg/m², 2 times / day, 1 to 14 days; cisplatin 60 mg/m² on day 1, need hydration, 21 day/cycle), operation after 2˜4 weeks, and postoperative chemotherapy of XP for 3 cycles 4˜6 weeks after surgery. Other Name: XP chemotherapy
Outcomes	Relapse‐free survival time/rate [ Time Frame: 3 years ]
Starting date	January 2011
Contact information	Xiangdong Cheng, MD, Zhejiang Cancer Hospital
Notes